Can I trust a purity figure quoted without a chromatogram?

I have the report as a PDF with the chromatogram on page two, so I can quote specifics.

Somebody stated this to me confidently and I would like to check it before repeating it.

I would accept a well-reasoned negative answer over a poorly sourced positive one.

What would count as evidence here, and does it exist?

On the detail: understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

It helps to be literal here: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

Compare purity within a single laboratory on the same method, never across laboratories.

Mechanically, gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

More usefully, temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

It helps to be literal here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.